Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP by Xuan Jin et al.
JOURNAL OF HEMATOLOGY
& ONCOLOGY
Jin et al. Journal of Hematology & Oncology 2012, 5:51
http://www.jhoonline.org/content/5/1/51RAPID COMMUNICATION Open AccessHomozygous A polymorphism of the
complement C1qA276 correlates with prolonged
overall survival in patients with diffuse large B
cell lymphoma treated with R-CHOP
Xuan Jin1, Huirong Ding2, Ning Ding3, Zhiying Fu3, Yuqin Song3* and Jun Zhu3*Abstract
Background: The precise mechanism of action for rituximab (R) is not fully elucidated. Besides antibody-dependent
cellular cytotoxicity (ADCC), complements may also play an important role in the clinical response to rituximab-
based therapy in diffuse large B cell lymphoma (DLBCL). The purpose of this study was to explore the relationship
between C1qA[276] polymorphism and the clinical response to standard frontline treatment with R-CHOP in DLBCL
patients.
Methods: Genotyping for C1qA[276A/G] was done in 164 patients with DLBCL. 129 patients treated with R-CHOP as
frontline therapy (R≥ 4 cycles) were assessable for the efficacy.
Results: Patients with homozygous A were found to have a higher overall response rate than those with
heterozygous or homozygous G alleles (97.3% vs. 83.7%,P= 0.068). The complete response rate in patients with
homozygous A was statistically higher than that in AG and GG allele carriers (89.2% vs. 51.1%,P= 0.0001). The overall
survival of patients with homozygous A was longer than that of the G allele carriers (676 days vs. 497 days,
P= 0.023). Multivariate Cox regression analysis showed that C1qA A/A allele was an independent favorable
prognostic factor for DLBCL patients treated with R-CHOP as first-line therapy.
Conclusion: These results suggest that C1qA polymorphism may be a biomarker to predict response to R-CHOP as
frontline therapy for DLBCL patients.
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Rituximab, a chimeric monoclonal antibody targeted
against the pan-B-cell marker CD20, has become a
mainstay in the therapy of B-cell non-Hodgkin lymph-
oma (NHL) [1]. Diffuse large B-cell lymphoma (DLBCL)
is the most common lymphoid neoplasm accounting for
approximately 30% to 40% of all NHLs. The introduction
of rituximab plus cyclophosphamide /doxorubicin /vin-
cristine /prednisone (R-CHOP) chemotherapy has sig-
nificantly improved the treatment outcome of DLBCL* Correspondence: songyuqin622@sina.com; zj@bjcancer.org
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reproduction in any medium, provided the orpatients, especially non-germinal center B cell-like (non-
GCB) subtypes [2-5]. However, not all patients with
DLBCL showed good response to R-CHOP chemother-
apy. Novel agents and prognostic factors are being
explored to improve treatment outcome [6-10].
In addition to synergistic activity with CHOP [11],
rituximab also appears to have an antitumor effect itself
[12]. Evidences for multiple antitumor mechanisms of
rituximab have been reported, including apoptosis
[13,14], complement-dependent cytotoxicity (CDC) [15-
17], and antibody-dependent cellular cytotoxicity
(ADCC) . It has been shown that the antitumor activity
of rituximab was completely abolished in syngeneic C1q
knockout mice and in a complement-depleted CVF
mouse model [18,19]. C1q is the trigger activation of theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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plexes, it’s formed by six trimers of A, B and C chains.
The C1qA gene, located on chromosome 1p36.3-p34.1,
contains several single nucleotide variations that are cur-
rently catalogued in the NCBI database. C1qA[276]
(rs172378) is located at the beginning of the second
exon. Racila E et al. reported that among 133 patients
with follicular lymphoma treated with single-agent ritux-
imab, polymorphisms in the C1qA[276] gene may have
affected the clinical response and duration of response
[20]. However, the impact of C1qA[276] polymorphism
on the efficacy of rituximab in DLBCL patients remains
unclear. In this study, we analyzed the relationships be-
tween C1qA polymorphism and the efficacy of primary
R-CHOP therapy in 129 patients with DLBCL.
Materials and methods
Patient characteristics and treatment protocol
A total of 164 consented patients who received R-CHOP
or R-CHOP-like chemotherapy between June 2007 and
December 2010 as a frontline regimen were included in
this retrospective study from Beijing Cancer Hospital.
All patients had CD20+ DLBCL according to the World
Health Organization classification as confirmed by our
Department of Pathology. Peripheral blood samples from
all lymphoma patients were obtained before the initi-
ation of therapy. The clinical research protocol was
approved by our Institutional Review Board (IRB).
R-CHOP chemotherapy was administered as follows:
one course of chemotherapy consisted of an intravenous
infusion of cyclophosphamide 750 mg/m2, adriamycin
50 mg/m2, vincristine 2 mg, and oral administration of
100 mg prednisone on days 1 to 5, which was repeated
every 3 weeks. Rituximab 375 mg/m2 was infused over 4
to 6 hours on day 1 before CHOP or CHOP-like chemo-
therapy was started. Of the 129 patients, 31 patients
received radiotherapy in involved-field. The response to
R-CHOP therapy was evaluated after completion of 2 to
3 courses of therapy and 1 to 2 months after completion
of all planned therapy, then every 3 months for the first
year and every 6 months thereafter until progression.
DNA extraction and genotyping
Genomic DNA was isolated from whole blood with the
Whole Blood Genome DNA isolation Kit (spin column)
according to the manufacturer’s instructions (Bioteke
Corporation, China). DNA was diluted in water to a final
stock concentration of 30 ng/ul, and 1ul was used in each
PCR reaction. Determination of the C1qA[276A/G] geno-
type was achieved blindly on coded specimens by Sanger
chain termination sequencing. Briefly, the genomic DNA
region of interest was amplified using forward 5’TAAAG
GAGACCAGGGGGAAC3’ and reverse 5’TTGAGGAG
GAGACGATGGAC3’primers. A first denaturation stepat 94°C for 3 min was followed by 35 cycles of denatur-
ation at 94°C for 30 s, annealing at 56°C for 30 s, exten-
sion at 72°C for 45 s, and a 10-min final extension step.
The PCR products were visualized on a 2% agarose gel
and then subjected to direct sequencing.
Definitions
Patients who had heterozygous (AG) or homozygous
G (GG) genotype of C1qA[276] were designated as G
carriers. Clinical responses were determined by physical
examination and confirmed by computed tomography or
ultrasound. The latter was only used for evaluating
superficial lymph nodes. The responses were scored
according to International Working Group criteria [21].
Overall survival (OS) was measured from day 1 of the
first cycle of R-CHOP until death for any cause or the
last follow-up available. The progression-free survival
(PFS) was calculated from day 1 of the first cycle of R-
CHOP to disease progression or death for any cause.
Statistical analysis
The clinical characteristics and response rate of the
patients were compared using Chi-square, Fisher exact
tests according to the C1qA SNP. Kaplan-Meier method
was used to estimate the differences of PFS and OS. The
Cox regression model was used to evaluate the prognos-
tic factors. Differences between groups were regarded as




The demographics and general characteristics of patients
in this study are summarized in Table 1. Enrolled in the
study were 81 female and 83 male patients. The median
age at diagnosis was 53 years (range, 15–90 years).
Eighty nine (54%) patients had stages 3 and 4 disease
and 50 (30%) patients had intermediate-to-high or high
International Prognostic Index (IPI) scores. Bone mar-
row was involved by lymphoma in 6 patients (4%) at the
time of diagnosis. R-CHOP followed by involved-field
radiation was given to 31 (19%) patients. One hundred
and twenty-nine patients received R-CHOP as a front-
line regimen and were therefore evaluable for this study.
A median of 6 cycles of rituximab therapy was given
(range, 4–14 cycles), and a median of 6 cycles of chemo-
therapy was given (range, 2–8 cycles).
C1qA276 polymorphism
The frequency of the C1qA[276A] allele among all patients
with lymphoma was 0.48, whereas the frequency of the
C1qA[276G] allele was 0.52. Forty-four patients (27%) were
homozygous A, whereas 50 patients (30%) were homozy-
gous G, and 70 patients (43%) were heterozygous. The








AA AG+GG AA AG/GG
Gender Bulky mass
Male 83 24 59 0.542 ≥10 cm 18 5 13 1.000
Female 81 20 61 <10 cm 146 39 107
Age Localized
≤60 102 26 76 0.620 yes 25 7 18 0.886
>60 62 18 44 no 139 37 102
B symptoms No Extra Nodal Site
positive 62 14 48 0.338 ≤1 122 31 91 0.484
negative 102 30 72 >1 42 13 29
LDH Incidence site
positive 77 20 57 0.816 lymph node 93 25 68 0.986
negative 87 24 63 extralymph 71 19 52
β2-MG IPI
positive 49 10 39 0.203 0~2 114 29 85 0.544
negative 106 32 74 3~5 50 15 33
Stage Molecular subtypes
I~II 75 19 56 0.691 GCB 28 6 22 0.872
III~IV 89 25 39 non-GCB 113 26 87
Abbreviations: AA /AG/GG indicates C1qA 276 genotype; MG: microglobulin; IPI: international prognostic index; GCB: germinal center B cell.
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our study was in Hardy-Weinberg equilibrium with regard
to the C1qA[276] polymorphism examined (P=0.06).Table 2 Prognostic factors and their correlation with
C1qA[276] genotype
Clinical parameters No. # Genotype χ2 P Value
Non-GCB
β2-MG AA AG+GGPatient characteristics according to C1qA allele status
No correlation was observed between patients’ disease
features and the C1qA[276] genotype (Table 1). In the
non-GCB subgroup, we observed the associations of the
C1qA[276] genotype with abnormal β2-microglobulin
level(defined as level > 3.0) (P= 0.012), but not B symp-
toms (P= 0.067). In the GCB subgroup, no association
was found between the C1qA[276] genotype status and
any of the factors (Table 2).positive 35 3 32 6.357 0.012
negative 72 22 50
B symptoms
positive 48 7 41 3.344 0.067
negative 65 19 46
GCB
β2-MG AA AG+GG
positive 4 2 2 0.218*
negative 22 4 18
B symptoms
positive 7 3 4 0.144*
negative 21 3 18
Abbreviations: AA /AG/GG indicates C1qA 276 genotype; MG: microglobulin;
IPI: international prognostic index; GCB: germinal center B cell.
*:Fisher’s Exact Test.Responses to R-chemotherapy according to the C1qA[276]
genotype
Of 129 patients evaluable for response to R-CHOP
chemotherapy, the overall response rate (ORR) was 88%
(113 of 129 patients), including complete response (CR)
62% (80 of 129 patients), and partial response (PR) rate
26% (33 of 129 patients). As shown in Table 3, homozy-
gous A patients showed a trend of higher response when
compared to the G allele carriers (P= 0.068). Higher CR
rate was observed in patients with homozygous A when
compared with G carriers (χ2 = 16.263, P= 0.0001).
Among the responders, CR was seen in 33 of 37 (89.2%)
homozygous A, 26 of 55 (47.3%) heterozygous, and 21 of
37 (56.8%) homozygous G patients (Table 3).In subgroup analysis, a statistically higher CR rate was
observed in the homozygous A patients compared with
G carriers (81.8% vs 42.9%, χ2 = 16.263, P= 0.002). This
was observed only in patients with non-GCB lymphoma.





AA(%) AG(%) GG(%) Total(%)
Complete response 33 (89.2) 26 (47.3) 21 (56.8) 80 (62.0)
Partial response 3 (8.1) 20 (60.6) 10 (27.0) 33 (25.6)
Overall response 36 (97.3) 46 (83.6) 31 (83.8) 113 (87.6)
Stable disease 0 (0) 0 (0) 0 (0) 0 (0)
Progression 1 (2.7) 9 (16.4) 6 (16.2) 16 (12.4)
Total 37 (100) 55 (100) 37 (100) 129 (100)
Abbreviations: AA /AG/GG indicates C1qA 276 genotype.
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After a median follow-up time of 524 days (range, 60–
2073 days), 32 (25%) patients relapsed or progressed, and
18 (14%) died. Seven patients participated in a clinical
trial evaluating everolimus (RAD001) and were censored
for progression-free survival (PFS) analysis. The homozy-
gous A patients had a median PFS of 623 days (range,
127–1177 days) versus 346 days (range, 42–1255 days)
for the rest patients. This longer PFS however did not
reach statistical significance (P=0.063) (Figure 1). Sur-
vival data was available for 129 patients. The overall sur-
vival was 676 days (range, 143–1364 days) for
homozygous A patients, and 497 days (range, 142–
1350 days) for GG and AG carriers (P=0.023, Figure 2).Figure 1 Kaplan-Meier curve of progression-free survival (PFS) accordThis difference was not seen when patients were subdi-
vided into GCB- and non-GCB lymphoma groups (data
not shown).
Multivariate analysis
A multivariate analysis was done to evaluate the follow-
ing variables: stage (stages 1,2 vs. 3,4), IPI score (0–2 vs.
3–5), age (≤60 vs.>60 years), lactate dehydrogenase level
(normal vs. abnormal), B symptoms (positive vs. nega-
tive), β2-microglobulin level (normal vs. abnormal),
extranodal involvement (≤1 site vs. ≥2 sites), bulky mass
(≥10 cm vs. <10 cm), and C1qA[276] (homozygous A vs.
G carriers). This analysis confirmed that high IPI score
(P= 0.033, HR 1.18, 95%CI 1.014-1.375) and abnormal
β2-microglobulin level (P= 0.001, HR 2.599, 95%CI
1.639-4.121) were poor prognostic factors. When homo-
zygous A was compared with the G carriers for overall
survival in this analysis, the relative risk for OS was
0.595 (P = 0.018, 95%CI 0.386-0.915), favoring AA
genotype.
Discussion
In this retrospective analysis, we found that homozygous
A -allele carriers of the gene C1qA[276] had better overall
response and higher complete response, and overall sur-
vival in DLBCL receiving R-CHOP. In subgroup analysis,
higher CR was associated with homozygous A –allele ining to C1qA[276] genotype..
Figure 2 Kaplan-Meier curve of overall survival (OS) according to C1qA[276] genotype..
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that this may be due to the small number of patients
that preclude reliable analysis.
As mentioned earlier, a previous study of 133 patients
with follicular lymphoma was done on the same C1qA
[276][20]. The study showed that in follicular lymphoma
patients treated with single agent rituximab, the duration
of response and time to progression was significantly
prolonged in patients with AA genotype. However, the
response rate was similar in both AA and GG genotypes.
In our study on DLBCL, the overall response and CR
rates were both better in patients with AA genotype of
C1qA[276]. Since the response was not based on PET/CT
scan which is more sensitive than CT alone, the response
rate could be different if PET/CT scan were used. PET/
CT scan should be considered for response evaluation in
future lymphoma studies.
It is unclear exactly how C1qA polymorphism affects
the lymphoma responses to R-CHOP chemotherapy. The
C1qA[276] G to A change is a synonymous polymorphism
which does not introduce amino acid substitution. It was
previously thought that such polymorphisms are “silent”,
but now there is a growing body of evidence indicating
that synonymous SNPs may alter the expression or func-
tion of a protein as well. For instance, synonymous SNPs
within the DRD2 transcript can reduce the stability of
the mRNA and thus the expression of the dopamine re-
ceptor [22]. Another mechanism that could lead to func-
tional effects from a synonymous SNP is biased codonusage [23]. Vasostatin is an NH2-terminal fragment of
human calreticulin, which is a natural receptor for C1q
expressed by many cell types. Pike SE et al. found that
vasostatin inhibit angiogenesis and tumor growth [24].
Interaction between calreticulin and C1q inhibits epithe-
lial cell development and angiogenesis [25]. Therefore,
C1q activity might affect tumor microenvironment or
angiogenesis [20]. Taken all these together, it seems that
C1q polymorphism may affect the expression level of
C1q, which may account for the differences in clinical
responses and treatment outcome in DLBCL. It will be
interesting to study the C1q level in lymphoma patients
prospectively and see whether it correlates with clinical
outcome in lymphoma patients.
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